## LAM RESEARCH CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data)

	Three Months Ended			Six Months Ended				
	Dec. 29, 2002		Dec. 30, 2001		Dec. 29, 2002		Dec. 30, 2001	
	(u	naudited)	(	unaudited)	(u	naudited)	(1	inaudited)
Total revenue	\$	184,569	\$	259,173	\$	382,089	\$	598,753
Cost and expenses: Cost of goods sold Cost of goods sold - restructuring charges (recoveries) Cost of goods sold - patent settlement		112,380 (301)		193,745 - 38,780		230,906 (301)		407,614 7,600 38,780
Total cost of goods sold		112,079		232,525		230,605		453,994
Gross margin		72,490		26,648		151,484		144,759
Operating expenses - research and development Operating expenses - selling, general and administrative Operating expenses - restructuring charges, net Total operating expenses		39,739 31,715 2,053 73,507		49,734 43,524 33,773 127,031		81,121 65,074 2,053 148,248		96,964 90,689 47,221 234,874
Operating income (loss)		(1,017)		(100,383)		3,236		(90,115)
Other income (expense): Gain/(loss) on equity derivative contracts in Lam stock Other income (expense), net		2,989		18,884 (386)		(16,407) 2,327		890 (571)
Income (loss) before income taxes		1,972		(81,885)		(10,844)		(89,796)
Income tax expense (benefit)		493		(30,230)		1,391		(29,221)
Net income (loss)	\$	1,479	\$	(51,655)	\$	(12,235)	\$	(60,575)
Net income (loss) per share:								
Basic	\$	0.01	\$	(0.41)	\$	(0.10)	\$	(0.48)
Diluted (1)	\$	0.01	\$	(0.41)	\$	(0.10)	\$	(0.48)
Number of shares used in per share calculation: Basic		125,411		125,674		126,171		125,507
Diluted (1)		128,537		125,674		126,171		125,507

<sup>(1)</sup> For the three-month period ended December 29, 2002, diluted net income per share includes the assumed exercise of employee stock options. The assumed conversion of the outstanding warrant and convertible subordinated 4% notes was antidilutive and therefore excluded from the computation of net income per share for the three-month period ended December 29, 2002. For the six-month period ended December 29, 2002, and the three- and six-month periods ended December 30, 2001, options, warrants and convertible subordinated notes were outstanding, but were excluded from the computation of diluted net loss per common share because the effect would have been antidilutive due to the net loss for the period.

## LAM RESEARCH CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)

	Dec. 29, 2002 (unaudited)		June 30, 2002 (1)		
Assets:					
Cash and short-term investments	\$	552,036	\$	874,205	
Accounts receivable, net		119,873		132,113	
Inventories		146,671		180,799	
Other current assets		143,204		168,307	
Total current assets		961,784	' <u>-</u>	1,355,424	
Equipment/leasehold improvements, net		57,511		67,496	
Restricted cash		61,907		70,983	
Other assets		153,013		138,388	
Total assets	\$	1,234,215	\$	1,632,291	
Liabilities and stockholders' equity:					
5% convertible debenture	\$	_	\$	309,763	
Other current liabilities		238,615		287,781	
Total current liabilities		238,615	\ <u></u>	597,544	
Other long-term debt and liabilities		372,848		359,691	
Stockholders' equity		622,752		675,056	
Total liabilities and					
stockholders' equity	\$	1,234,215	\$	1,632,291	

<sup>(1)</sup> Derived from audited financial statements